Dublin, Jan. 27, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/x4d595/sustained_release) has announced the addition of the "Sustained Release Injectables" report to their offering.
The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency addresses several important health care issues. Less frequent dosing is believed to improve patient safety, reduce the incidence of injection site complications and improve compliance with drug protocols. Sustained release formulations mitigate the bolus effect at the time of injection, and thus have a salutary influence on drug side effects.
All of these advantages, along with the need for fewer patient caregiver visits (for practitioner-administered drugs) have a positive, downward impact on overall healthcare costs. Currently approved sustained release injectables rely on a spectrum of branded formulation technologies to modulate the drug's release profile post-injection. Typically off-patent or generic drugs, they include drug therapies for almost a dozen major therapeutic segments, including neurological conditions, metabolic diseases, oncology, pain management and reproductive health.
As the incidence and prevalence of chronic illnesses increases with the aging population, the attraction and interest in sustained release injectables to 2022 will increase.
Sustained Release Injectables - What You Will Learn
- What are the marketed sustained release injectable drug products, what sustained release formulation technologies are used, and who markets them?
- What are the major factors driving sustained release injectable drug demand?
- What sustained release injectable drug candidates are in late-stage clinical development and what is their potential impact?
- How important are drug developer-formulation technologist relationships in the sustained release market segment, and what are the key alliances in the industry?
- What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for sustained release injectable drug products?
- In what therapeutic market segments do sustained release injectables compete? What is their market share today? What will it be in 2022? What is their expected growth rate?
- What are the significant economic, technology, and regulatory factors affecting the market for sustained release injectables?
Key Topics Covered:
1. Executive Summary
- Injectable Drug Market Dynamics
- The Trend toward Self-Administration
- Injectable Drug Formulation Technology
- Innovation in Injectable Device Designs
- Therapeutic Demand Drivers
- Market Factors
- Competitive Landscape
- Risk Factors
2. Sustained Release - Branded Formulation Technologies
- Biodegradable Polymers
- Branded SR Formulation Technologies
- Physical Process Control Methods
3. Sustained Release Injectables - Development Factors
- Formulation Factors
- Stability
- Lyophilization
- Packaging
- Administration Factors
4. SR Injectables - Product Analysis & Market Sector ForecastAddiction
- Naltrexone
- Diabetes
- Exenatide
- Infectious Disease
- Interferon
- Hormone Deficiency
- Estradiol
- Somatropin
- Testosterone
- Metabolic Diseases
- Acromegaly
- Lanreotide
- Octreotide
- Neurology
- Aripiraole
- Fluphenazine
- Haloperidol
- Paliperidone
- Olanzapine
- Risperidone
- Oncology
- Leukemia
- Vincristine
- Lymphoma
- Cytarabine
- Prostate
- Goserelin
- Leuprolide
- Triptorelin
- Pain Management
- Bupivacaine
- Reproductive Health
- Medtroxyprogesterone
5. Development-stage SR Injectables
6. Company Profiles
For more information visit http://www.researchandmarkets.com/research/x4d595/sustained_release
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infusions and Injectables , Needles and Syringes


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Washington Post Publisher Will Lewis Steps Down After Layoffs
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Anta Sports Expands Global Footprint With Strategic Puma Stake 



